Article Data

  • Views 5358
  • Dowloads 718

Original Research

Open Access

Controlling the polycythemia effect associated with TRT

  • Shane M. Kelleher1,*,

1InfiniT Men’s Health Clinic, Burleson, TX 76028, USA

DOI: 10.22514/jomh.2024.010 Vol.20,Issue 1,January 2024 pp.73-80

Submitted: 17 August 2023 Accepted: 25 September 2023

Published: 30 January 2024

*Corresponding Author(s): Shane M. Kelleher E-mail:


The goal of this study was to determine how to minimize the secondary polycythemia effect observed in patients on testosterone replacement therapy (TRT). Patient hemoglobin, estradiol (E2) and total testosterone (TT) levels were used in this study to determine when a patient became “stable” on treatment. Stability was defined in this study as the point at which a patient’s symptoms have resolved, secondary polycythemia has stopped, and testosterone cypionate (TC) dosage has remained consistent for at least three months. Currently, secondary polycythemia associated with TRT is commonly being controlled by frequent blood donations, or therapeutic phlebotomies. However, this study shows that it is possible to minimize fluctuations in TT and E2 levels, which then minimizes side effects including secondary polycythemia. In this study, we found that the patients stabilized at TT levels between 605–1051 ng/dL. The effects of stable TC dosing were tracked and discussed in terms of total cholesterol, Prostate Specific Antigen (PSA) and A1c levels as well. These were not necessarily the focus of the study, but significant trends were noted once data was collected to warrant their inclusion in the study.


Testosterone replacement therapy; Total testosterone; Testosterone cypionate; Estradiol; Stabilization

Cite and Share

Shane M. Kelleher. Controlling the polycythemia effect associated with TRT. Journal of Men's Health. 2024. 20(1);73-80.


[1] Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. The Journal of Clinical Endocrinology & Metabolism. 2017; 102: 1161–1173.

[2] Regenx Health. LabCorp vs. quest laboratories serum testosterone assays & reference ranges. 2020. Available at: (Accessed: 05 June 2023).

[3] Hormone Therapeutics. Here’s what you should know more about testosterone levels. 2016. Available at: (Accessed: 05 June 2023).

[4] Pantalone K. Why are testosterone levels decreasing? 2022. Available at: (Accessed: 13 May 2023).

[5] Lokeshwar SD, Patel P, Fantus RJ, Halpern J, Chang C, Kargi AY, et al. Decline in serum testosterone levels among adolescent and young adult men in the USA. European Urology Focus. 2021; 7: 886–889.

[6] Snyder PJ, Matsumoto AM, Martin KA. Testosterone treatment of male hypogonadism. 2022. Available at: (Accessed: 03 May 2023).

[7] Stevens R. Gold standard TRT. 2018. Available at: (Accessed: 07 May 2023).

[8] Bhasin S. Testosterone replacement in aging men: an evidence-based patient-centric perspective. Journal of Clinical Investigation. 2021; 131: e146607.

[9] Mayo Clinic. Testosterone therapy: Potential benefits and risks as you age. 2022. Available at: (Accessed: 03 May 2023).

[10] Mohammadi-Shemirani P, Chong M, Pigeyre M, Morton RW, Gerstein HC, Paré G. Effects of lifelong testosterone exposure on health and disease using Mendelian randomization. eLife. 2020; 9: e58914.

[11] Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels. JAMA. 2015; 314: 570–581.

[12] Terranella R. Testosterone replacement therapy dosing and dosage considerations. 2014. Available at: (Accessed: 03 May 2023).

[13] Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men. JAMA Psychiatry. 2019; 76: 31–40.

[14] Halpern JA, Brannigan RE. Testosterone deficiency. JAMA. 2019; 322: 1116.

[15] Chasland LC, Yeap BB, Maiorana AJ, Chan YX, Maslen BA, Cooke BR, et al. Testosterone and exercise: effects on fitness, body composition, and strength in middle-to-older aged men with low-normal serum testosterone levels. American Journal of Physiology-Heart and Circulatory Physiology. 2021; 320: H1985–H1998.

[16] Barone B, Napolitano L, Abate M, Cirillo L, Reccia P, Passaro F, et al. The role of testosterone in the elderly: what do we know? International Journal of Molecular Sciences. 2022; 23: 3535.

[17] Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. The Journal of Clinical Endocrinology & Metabolism. 2010; 95: 3955–3964.

[18] Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A. ARIMIDEX™: a new oral, once-a-day aromatase inhibitor. The Journal of Steroid Biochemistry and Molecular Biology. 1995; 53: 175–179.

[19] Aveta A, Cilio S, Contieri R, Spena G, Napolitano L, Manfredi C, et al. Urinary MicroRNAs as biomarkers of urological cancers: a systematic review. International Journal of Molecular Sciences. 2023; 24: 10846.

[20] Jepson JH, Lowenstein L. Inhibition of the stem cell action of erythropoietin by estradiol valerate and the protective effects of 17-á-hydroxyprogesterone caproate and testosterone propionate. Endocrinology. 1967; 80: 430–434.

[21] Lindemann R. Erythropoiesis inhibiting factor (EIF) the inhibitory effect of oestrogens on erythropoiesis and the content of oestrogens in the urinary EIF. Scandinavian Journal of Haematology. 1973; 11: 319–324.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.9 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (

Submission Turnaround Time